Sugi Predict

Sugi Predict / Compounds / SCHEMBL2582442

SCHEMBL2582442

SCHEMBL2582442

Fc1cc(Br)c2ncccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 4/20 0.46
▸ CCR8 P51685 4/20 0.46
▸ HTT P42858 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TP53 P04637 2/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ CCR5 P51681 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MMP2 P08253 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ GMNN O75496 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ MMP8 P22894 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31276857 1.00 CCR1 (0.46) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL9275208 0.79 SLC40A1 (0.50) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL2696188 0.78 PSMD14 (0.62) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL15007502 0.78 KDM4E (0.48) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL3569578 0.78 CCR1 (0.50) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL7441724 0.78 HSP90AA1 (0.54) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL31373519 0.78 CCR1 (0.45) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL26650869 0.78 CCR1 (0.45) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL3930034 0.78 PTPN6 (0.44) CCR1CCR8HTTKDM4ESMN1; SMN2
SCHEMBL196509 0.76 LMNA (0.64) CCR1CCR8HTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729508-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA Arcus Biosciences, Inc. (US) 2026-04-22 — — EP disclosed
US-20250214930-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. (US) 2025-07-03 — — US disclosed
CN-120152713-A Tricyclic aryl derivatives and compositions and methods thereof 昂胜医疗科技公司 2025-06-13 — — CN disclosed
EP-4561562-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF Ensem Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
CN-119118872-A Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors 艾库斯生物科学有限公司 2024-12-13 — — CN disclosed
US-20240408169-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-12-12 — — US disclosed
US-12103907-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha ARCUS BIOSCIENCES, INC. (US) 2024-10-01 — — US disclosed
CN-115298165-B Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors 艾库斯生物科学有限公司 2024-09-17 — — CN disclosed
US-20240254079-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. 2024-08-01 — — US disclosed
CN-117736222-A MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures 烨辉医药科技(上海)有限公司 2024-03-22 — — CN disclosed
CN-1812984-A Benzofuranyl-piperazinyl and benzothienyl-piperazinyl quinolines as 5-hydroxytryptamine reuptake inhibitors WHETH CORP (US) 2006-08-02 — — CN disclosed
EP-1641785-A2 BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS Wyeth (US) 2006-04-05 — — EP disclosed
US-20050059673-A1 Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use WYETH 2005-03-17 — — US disclosed
WO-2004099191-A2 BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS WYETH (US) 2004-11-18 — — WO disclosed
US-4812471-A Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones PFIZER INC. (US) 1989-03-14 — — US disclosed
US-4753956-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1988-06-28 — — US disclosed
US-4689336-A Hypoglycemic 5-substituted oxazolidine 2,4-diones PFIZER INC. (US) 1987-08-25 — — US disclosed
US-4565820-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1986-01-21 — — US disclosed
US-4431810-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1984-02-14 — — US disclosed
US-4342771-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1982-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214930-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA HIF1AN, HIF1A, EGLN2 CCR1 1690/4885CCR8 1888/4885HTT 358/4885
US-20240254079-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA HIF1AN, HIF1A, EGLN2 CCR1 1690/4885CCR8 1888/4885HTT 358/4885
US-12103907-B2 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha HIF1AN, HIF1A, EGLN2 CCR1 1690/4885CCR8 1888/4885HTT 358/4885
US-20240408169-A1 CYCLIN INHIBITORS CCNI, CDK2, CDK1 CCR1 2663/4885CCR8 3213/4885HTT 3827/4885
US-20050059673-A1 Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use TPH1, TPH2, HTR2C CCR1 4836/4885CCR8 4827/4885HTT 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.